Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Triple Negative Breast Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Neoplasms 2Melanoma 2Lung Neoplasms 2Endometrial Neoplasms 2Breast Neoplasms 2Bile Duct Neoplasms 2Uterine Cervical Neoplasms 1Thoracic Neoplasms 1SCLC 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Prostatic Neoplasms 1Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Osteosarcoma 1Non Small Cell Lung Cancer NSCLC 1Neoplasms by Site 1Neoplasm Metastasis 1Lung Diseases 1High Grade Serous Carcinoma 1Hereditary Sensory and Autonomic Neuropathies 1Fallopian Tube Neoplasms 1Extensive Stage Small Cell Lung Cancer 1Cholangiocarcinoma 1Carcinosarcoma 1Carcinoma, Transitional Cell 1

Interventions

tremelimumab 1olaparib 1durvalumab 1ceralasertib 1adavosertib 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma × ceralasertib × Clear all
NCT02937818 2024-06-07

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

AstraZeneca

Phase 2 Completed
72 enrolled 29 charts
Thoracic

Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡